Readable research linked to original sources

Articles

Browse normalized, publication-ready research with direct links to its evidence and source.

2 articles

Newest first

Research Article 2024CC BYFree full text

Comparative efficacy and safety of stiripentol, cannabidiol and fenfluramine as first-line add-on therapies for seizures in Dravet syndrome: A network meta-analysis.

Renzo Guerrini, Catherine Chiron, Delphine Vandame, Warren Linley, Toby Toward

Objectives Stiripentol, fenfluramine, and cannabidiol are licensed add-on therapies to treat seizures in Dravet Syndrome (DS). There are no direct or indirect comparisons assessing their full licensed dose regimens, across different jurisdictions, as first-line add-on therapies in DS. Methods We conducted a systematic review and frequentist network meta-analysis (NMA) of randomized controlled trial (RCT) data for…

Epilepsia Open Europe PMC

Open article record in new tab ↗

Research Article 2021CC BYFree full text

Results From an Italian Expanded Access Program on Cannabidiol Treatment in Highly Refractory Dravet Syndrome and Lennox-Gastaut Syndrome.

Luigi Francesco Iannone, Gabriele Arena, Domenica Battaglia, Francesca Bisulli, Paolo Bonanni, Antonella Boni +37 more

Background: Purified cannabidiol (CBD) was administered to highly refractory patients with Dravet (DS) or Lennox-Gastaut (LGS) syndromes in an ongoing expanded access program (EAP). Herein, we report interim results on CBD safety and seizure outcomes in patients treated for a 12-month period. Material and Methods: Thirty centers were enrolled from December 2018 to December 2019 within the open-label prospective EA…

Frontiers in Neurology Europe PMC

Open article record in new tab ↗